The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediatedex vivoplatelet function in acute myocardial infarction
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Platelets
- Vol. 20 (5), 334-340
- https://doi.org/10.1080/09537100903085927
Abstract
ARC1779 is an aptamer, which blocks binding of the von Willebrand Factor (VWF) A1 domain to platelet GPIb receptors. VWF is increased in the elderly an in the setting of acute myocardial infarction (AMI), as reflected by increased shear-dependent platelet function. We hypothesized that ARC1779 concentration-dependently inhibits ex vivo platelet function, and that this concentration effect relationship may be shifted in patients with AMI. We studied ex vivo dose response curves for ARC1779 on VWF activity, shear-dependent platelet function, and agonist-induced platelet aggregation. We included patients with AMI on standard treatment (n = 40), young (n = 20) and elderly controls (n = 20) in this ex vivo dosing study. AMI patients displayed ∼2-fold increased plasma levels of VWF activity as compared to controls. ARC1779 inhibited VWF activity (IC90: ∼3–4 µg/mL) and shear dependent platelet function (Platelet Function Analyzer (PFA-100), IC50: ∼0.5–0.9 µg/mL and Cone and Plate Analyzer (CPA), IC50: ∼0.1–0.4 µg/mL in citrated blood) at comparable concentrations in all groups. In contrast to GPIIb/IIIa antagonists, ARC1779 did not inhibit platelet aggregation induced by ADP, collagen or arachidonic acid at concentrations (10 µg/mL) that fully inhibited VWF dependent platelet function. ARC1779 potently and specifically inhibits VWF activity and VWF dependent platelet function, even in the setting of AMI where VWF activity is increased.Keywords
This publication has 27 references indexed in Scilit:
- Von Willebrand Factor in Cardiovascular DiseaseCirculation, 2008
- Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapyPlatelets, 2008
- First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy VolunteersCirculation, 2007
- Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACSJournal of Thrombosis and Haemostasis, 2006
- von Willebrand factor, endothelial dysfunction, and cardiovascular diseaseJournal of Thrombosis and Haemostasis, 2006
- Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet functionJournal of Thrombosis and Haemostasis, 2006
- Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial InfarctionCirculation, 2004
- Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirinBlood, 2003
- Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patientsPlatelets, 2002
- Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunctionJournal of Laboratory and Clinical Medicine, 2001